These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 29733817)

  • 1. Predictors of DMPA-SC continuation among urban Nigerian women: the influence of counseling quality and side effects.
    Liu J; Shen J; Diamond-Smith N
    Contraception; 2018 Nov; 98(5):430-437. PubMed ID: 29733817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuation of subcutaneous or intramuscular injectable contraception when administered by facility-based and community health workers: findings from a prospective cohort study in Burkina Faso and Uganda.
    MacLachlan E; Atuyambe LM; Millogo T; Guiella G; Yaro S; Kasasa S; Bukenya J; Nyabigambo A; Mubiru F; Tumusiime J; Onadja Y; Zan LM; Goeum/Sanon C; Kouanda S; Namagembe A
    Contraception; 2018 Nov; 98(5):423-429. PubMed ID: 30125558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuation of injectable contraception when self-injected vs. administered by a facility-based health worker: a nonrandomized, prospective cohort study in Uganda.
    Cover J; Namagembe A; Tumusiime J; Nsangi D; Lim J; Nakiganda-Busiku D
    Contraception; 2018 Nov; 98(5):383-388. PubMed ID: 29654751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Introducing the subcutaneous depot medroxyprogesterone acetate injectable contraceptive via social marketing: lessons learned from Nigeria's private sector.
    Liu J; Schatzkin E; Omoluabi E; Fajemisin M; Onuoha C; Erinfolami T; Ayodeji K; Ogunmola S; Shen J; Diamond-Smith N; Sieverding M
    Contraception; 2018 Nov; 98(5):438-448. PubMed ID: 30071196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of self-administration versus provider-administered injection of subcutaneous depot medroxyprogesterone acetate on continuation rates in Malawi: a randomised controlled trial.
    Burke HM; Chen M; Buluzi M; Fuchs R; Wevill S; Venkatasubramanian L; Dal Santo L; Ngwira B
    Lancet Glob Health; 2018 May; 6(5):e568-e578. PubMed ID: 29526707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors Affecting Continued Use of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC): A Secondary Analysis of a 1-Year Randomized Trial in Malawi.
    Burke HM; Chen M; Buluzi M; Fuchs R; Wevill S; Venkatasubramanian L; Santo LD; Ngwira B
    Glob Health Sci Pract; 2019 Mar; 7(1):54-65. PubMed ID: 30894394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interest in self-administration of subcutaneous depot medroxyprogesterone acetate in the United States.
    Upadhyay UD; Zlidar VM; Foster DG
    Contraception; 2016 Oct; 94(4):303-13. PubMed ID: 27326938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of job aids on knowledge retention among Patent and Proprietary Medicine Vendors trained to administer injectable contraceptives: longitudinal results from implementation science in Nigeria.
    Chace Dwyer S; Jain A; Ishaku SM; Okunade FT; Uzomba C; Adebayo A; Tobey E
    BMC Public Health; 2019 Oct; 19(1):1362. PubMed ID: 31651273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuation of self-injected versus provider-administered contraception in Senegal: a nonrandomized, prospective cohort study.
    Cover J; Ba M; Drake JK; NDiaye MD
    Contraception; 2019 Feb; 99(2):137-141. PubMed ID: 30439358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Young Women's Experiences With Subcutaneous Depot Medroxyprogesterone Acetate: A Secondary Analysis of a One-Year Randomized Trial in Malawi.
    Burke HM; Chen M; Packer C; Fuchs R; Ngwira B
    J Adolesc Health; 2020 Nov; 67(5):700-707. PubMed ID: 32389457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depot medroxyprogesterone acetate pioneers. A retrospective study at a North Carolina Health Department.
    Potter LS; Dalberth BT; Cañamar R; Betz M
    Contraception; 1997 Nov; 56(5):305-12. PubMed ID: 9437559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Women's satisfaction, use, storage and disposal of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) during a randomized trial.
    Burke HM; Chen M; Buluzi M; Fuchs R; Wevill S; Venkatasubramanian L; Dal Santo L; Ngwira B
    Contraception; 2018 Nov; 98(5):418-422. PubMed ID: 29758176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Client and provider experiences with self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) in Malawi.
    Burke HM; Packer C; Buluzi M; Healy E; Ngwira B
    Contraception; 2018 Nov; 98(5):405-410. PubMed ID: 29706227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety of subcutaneously administered depot medroxyprogesterone acetate (104mg/0.65mL): A systematic review.
    Dragoman MV; Gaffield ME
    Contraception; 2016 Sep; 94(3):202-15. PubMed ID: 26874275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies to improve adherence and acceptability of hormonal methods of contraception.
    Halpern V; Lopez LM; Grimes DA; Stockton LL; Gallo MF
    Cochrane Database Syst Rev; 2013 Oct; (10):CD004317. PubMed ID: 24163097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Cyclofem in the treatment of depot medroxyprogesterone acetate induced amenorrhea.
    Piya-Anant M; Koetsawang S; Patrasupapong N; Dinchuen P; d'Arcangues C; Piaggio G; Pinol A
    Contraception; 1998 Jan; 57(1):23-8. PubMed ID: 9554247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized clinical trial of self versus clinical administration of subcutaneous depot medroxyprogesterone acetate.
    Beasley A; White KO; Cremers S; Westhoff C
    Contraception; 2014 May; 89(5):352-6. PubMed ID: 24656555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Introduction of Community-Based Provision of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in Benin: Programmatic Results.
    Okegbe T; Affo J; Djihoun F; Zannou A; Hounyo O; Ahounou G; Bangbola KA; Harris N
    Glob Health Sci Pract; 2019 Jun; 7(2):228-239. PubMed ID: 31171559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depo Provera. Position paper on clinical use, effectiveness and side effects.
    Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
    Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Injectable contraception: emerging evidence on subcutaneous self-administration.
    Lerma K; Goldthwaite LM
    Curr Opin Obstet Gynecol; 2019 Dec; 31(6):464-470. PubMed ID: 31567445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.